Company Overview
Disc Medicine, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases within the United States. The company functions within the Healthcare sector, specifically targeting the Biotechnology industry, which implies a focus on high-risk, high-reward research and development projects aimed at addressing significant medical needs. As of the latest available data, the firm carries a market capitalization of $2.22B and employs a workforce of 155 individuals. The market cap figure of $2.22B indicates that the market assigns a substantial valuation to the company's potential pipeline, despite the absence of current annual revenue data, suggesting significant investor confidence in future commercialization prospects rather than existing sales performance.
Financial Health
The company reports net income of $-212,184,000 and EBITDA of $-234,888,992, while revenue figures are not currently disclosed in the available data. The gap between revenue and net income reveals a cost structure where operating expenses, likely heavily weighted toward research and development and administrative costs typical of clinical-stage biotech firms, far exceed any current revenue generation. Free cash flow stands at $-111,715,624, which indicates that the company is burning cash rapidly to fund its operations and development efforts rather than generating positive cash flow from its current business activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved profitability or that revenue is insufficient to cover the high fixed costs associated with its clinical-stage business model. On the liability side, the company holds $791.15M in cash against $31.02M in debt, resulting in a debt-to-equity ratio of 4.19, which suggests a highly leveraged balance sheet relative to equity but provides a robust cash buffer against short-term obligations. The current ratio is an exceptionally high 21.94, indicating that the company possesses overwhelming short-term liquidity relative to its current liabilities, likely due to the massive cash hoard relative to minimal debt. Return on Equity is -35.9% and Return on Assets is -22.5%, metrics that reveal management is currently using shareholder and asset bases to generate losses rather than returns, a common but financially risky characteristic of companies in the early phases of drug development.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the lack of net income, while the forward P/E is -7.74, implying that the market prices the stock based on anticipated future earnings that are currently expected to be negative. The price-to-book ratio is 2.98, indicating that the market values the company at nearly three times its book value, reflecting a premium assigned to the intangible assets and potential value of its clinical pipeline. The price-to-sales ratio is N/A and the EV/EBITDA is -6.21, suggesting that traditional valuation multiples based on current sales or earnings are not applicable, and the negative EV/EBITDA confirms the company is in a cash-burning phase where investors are pricing in future success rather than current cash flow generation. The 52-week trading range spans from a low of $30.82 to a high of $99.50; without a specific current price provided in the facts, the valuation range highlights the significant volatility the stock has experienced over the last year. The beta is 2.66, which means the stock is expected to be 2.66 times more volatile than the broader market, indicating that price movements will likely be amplified significantly by general market fluctuations.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning historical growth rates cannot be calculated from the current data, and thus no comparison can be made regarding whether earnings are growing faster or slower than revenue. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which signifies that the firm reinvests all available capital into research, development, and commercialization efforts rather than distributing income to shareholders. Given the net income of $-212,184,000, a dividend payout is financially unsustainable at this stage, reinforcing the strategy of capital retention for growth. The overall growth and income profile for Disc Medicine, Inc. is characterized by a complete absence of current income distribution and measurable revenue growth, relying entirely on the potential future success of its hematologic disease treatments to drive value creation.